Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA
ConditionColorectal Cancer Recurrent
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-100
SponsorKoo Foundation Sun Yat-Sen Cancer Center
About this trial
This single-center, phase II clinical trial investigates the diagnostic efficacy of Ga-68-FAPI-46 PET scans in detecting colorectal cancer (CRC) recurrence during post-treatment surveillance, particularly in patients with elevated serum carcinoembryonic antigen (CEA). The study compares the sensitivity, specificity, and accuracy of Ga-68-FAPI-46 PET with the conventional F-18-FDG PET scans, aiming to enhance recurrence detection in CRC patients who underwent curative surgery. Thirty participants will be enrolled and monitored through imaging studies and clinical follow-up.
Eligibility criteria
Qualifiers
Age ≥ 20 years old
The surgical intervention for colorectal cancer aims for curative resection, with the goal of achieving a disease-free status that persists for six months or more, as assessed clinically and through imaging studies.
Already performed or scheduled for FDG PET scanning examination. (5) Able to lie flat for at least 30 minutes.
Signing the subject consent form.
Disqualifiers
pregnant woman and breastfeeding women
severe renal impairment (eGRF< 30ml/min)
Known or suspected allergy to radiopharmaceuticals
Simultaneously or previously diagnosed with malignant tumors other than colorectal cancer.
Trial design
Treatments tested in this trial
- Ga-68-FAPI-46
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov